Biocon Limited (BOM:532523)
India
· Delayed Price · Currency is INR | Market Cap | 381.66B |
| Revenue (ttm) | 147.62B |
| Net Income (ttm) | 8.04B |
| Shares Out | n/a |
| EPS (ttm) | 6.71 |
| PE Ratio | 47.45 |
| Forward PE | n/a |
| Dividend | 0.50 (0.16%) |
| Ex-Dividend Date | Jul 5, 2024 |
| Volume | 139,636 |
| Average Volume | 116,338 |
| Open | 326.75 |
| Previous Close | 326.40 |
| Day's Range | 308.80 - 328.05 |
| 52-Week Range | 270.00 - 404.60 |
| Beta | n/a |
| RSI | 44.21 |
| Earnings Date | Apr 25, 2025 |
About Biocon
Biocon Limited, together with its subsidiaries, engages in the manufacture and sale of biotechnology products and research services in India, Brazil, Singapore, and internationally. It operates through four segments: Generics, Novel Biologics, Biosimilars, and Research Services. The company offers generic formulations and API products, including anti-diabetics, immunosuppressants, multiple sclerosis, anti-cancer/oncology, and other products; novel biologics products, such as head and neck cancer molecule; novel pipeline products comprising psor... [Read more]
Financial Performance
In 2023, Biocon's revenue was 147.56 billion, an increase of 32.05% compared to the previous year's 111.74 billion. Earnings were 10.23 billion, an increase of 120.99%.
Financial StatementsNews
Biocon shares jump over 2% after EU panel’s positive nod for denosumab biosimilars
Shares of Biocon Ltd rose 2.07% to ₹318.30 in early trade on April 28, 2025, after its subsidiary received a major boost from European regulators. The Committee for Medicinal Products for Human Use (C...
Biocon to raise Rs 4,500 crore via QIP or other routes
Biocon Limited has announced that its board of directors has approved a proposal to raise up to ₹4,500 crore through a mix of instruments, including equity shares, convertible securities, non-converti...
Eris Lifesciences, Lupin and Biocon shares in focus as Novo Nordisk exits Rs 800 crore Human Mixtard brand, says report
Shares of Eris Lifesciences, Lupin, and Biocon were in focus on April 23 after pharmaceutical major Novo Nordisk announced the discontinuation of its Human Mixtard insulin brand in India — one of the ...
Biocon shares in focus ahead of April 23 board meeting to consider fundraise proposal
Shares of Biocon Limited are expected to be in focus in the upcoming trading sessions as the company has informed exchanges about an important board meeting scheduled for April 23, 2025, to consider a...
Biocon shares jump 3% as its subsidiary secures US market entry for Yesafili
Biocon Ltd. shares surged 3% after its subsidiary, Biocon Biologics Ltd., announced a major breakthrough in the U.S. market with the confirmed entry of Yesafili™ (aflibercept-jbvf)—an interchangeable ...
Biocon Biologics secures U.S. market entry for Yesafili™, an interchangeable biosimilar to Eylea®
Biocon Biologics Ltd., a subsidiary of Biocon Ltd., has announced a significant milestone in its U.S. expansion with the confirmation of a market entry date for Yesafili™ (aflibercept-jbvf), an interc...
Biocon shares rise over 3% as USFDA approves bevacizumab biosimilar Jobevne™ for cancer treatment
Shares of Biocon Ltd surged 3.07% to ₹315.70 in Friday’s early trade after its subsidiary, Biocon Biologics Ltd (BBL), secured approval from the U.S. Food and Drug Administration (USFDA) for its bevac...
Top stocks to watch today, April 11: Tata Steel, Infosys, TCS, BHEL, Aurobindo Pharma, Biocon and more
The Indian stock market could open on a negative note today (Friday, April 11), as indicated by Gift Nifty. At 8:27 AM, Gift Nifty was seen trading at 22,934, down 0.48%. The Indian stock market may o...
Biocon Biologics receives U.S. FDA approval for bevacizumab biosimilar JOBEVNE
Biocon Biologics Ltd (BBL), a subsidiary of Biocon Ltd (BSE: 532523, NSE: BIOCON), has received approval from the U.S. Food and Drug Administration (FDA) for its bevacizumab biosimilar, Jobevne™ (beva...
Biocon shares drop over 6% today; Board approves Rs 600 crore fundraise via commercial papers
Shares of biotechnology major Biocon Ltd slipped over 6% to ₹307.80 during Monday’s trade, following an announcement that the company’s board had approved raising up to ₹600 crore through the issuance...
Pharma stocks reel under pressure: Biocon plunges 5.64%, IPCA Labs slips 4.67%, Glenmark down 3.56%; Torrent Pharma lone gainer
Pharmaceutical stocks witnessed heavy selling pressure in early trade on Monday, dragged down by broader market weakness amid rising global trade tensions. At 9:28 AM, benchmark indices Sensex and Nif...
Stocks to watch today: Tata Motors, ITC, Dr. Reddy’s, IndusInd Bank, L&T, Biocon, Indusind Bank, Astra Zenecca in focus
Indian stock markets are set to react to a slew of corporate announcements and macro developments on Monday, with several major and midcap companies in the spotlight. Tata Motors will likely be under ...
Sun Pharma, Dr. Reddy’s, Welspun India, Bharat Forge, Lupin, Biocon, UPL, Aurobindo, Indo Count, Cummins India and over 100 other Indian companies could face major impact from 26% US tariff hike
In a major escalation of trade tensions, US President Donald Trump on April 2 announced a 26% reciprocal tariff on imports from India, citing high tariffs imposed by India on American goods. The move ...
Kiran Mazumdar Shaw Compares Bengaluru To Ecuador's Well-Designed Streets: "Hang Your Head In Shame"
Biocon chief Kiran Mazumdar Shaw on Thursday criticised Bengaluru's infrastructure and compared the city's streets to those in Ecuador.
Biocon stock in focus today: Biocon Pharma gets US FDA nod for norepinephrine injection
Biocon Limited announced on March 24, 2025, that its wholly owned subsidiary, Biocon Pharma Limited, has received approval from the U.S. Food and Drug Administration (US FDA) for its Abbreviated New D...
Stocks to watch today, March 10: Sun Pharma, ONGC, JSW Steel, Biocon, Omaxe and more
The Indian stock market has been experiencing significant movement, with the BSE Sensex rising by 1,134.48 points (1.55%) and the NSE Nifty gaining 427.8 points (1.93%) last week. However, today, Gift...
Stocks to watch today: TCS, IndiGo, BEL, Biocon, JSW Energy in Focus; Bajaj Finserv, Ola Electric, Go Fashion Decline on March 7, 2025
Indian stock markets will track key corporate developments today as multiple companies announced expansion plans, order wins, investments, and management changes. Stocks in Focus (Positive): TCS: Expa...
Stocks to Watch today: Kalpataru Projects, Bharat Electronics, Biocon, RVNL, Brigade, IndiGo, Power Grid in focus on March 7, 2025
Indian markets will track key corporate developments today, with several stocks in focus due to order wins, expansion plans, fundraising activities, and leadership changes. Stocks in News (Positive): ...
Stocks to watch today: Power Grid, ONGC, Adani Wilmar, Biocon, Apollo Hospitals, JSW Energy among stocks in focus on March 5, 2025
Indian stock markets are set for a volatile session today, with several major stocks in focus due to key developments across various sectors. Power Grid has been declared the successful bidder for thr...
Biocon Pharma secures US FDA approvals for Lenalidomide, Dasatinib, and Rivaroxaban tablets
Biocon Pharma Limited, a wholly owned subsidiary of Biocon Limited, has received final approvals from the U.S. Food and Drug Administration (U.S. FDA) for multiple Abbreviated New Drug Applications (A...
Pharma Stocks: Glenmark down 2.43%, Divi’s Lab slips 2.10%, Biocon drops 2.57%, Glaxo plunges 3.44%, Nifty down 1.22%
The pharmaceutical sector experienced a broad-based decline, contributing to the overall market weakness as Nifty fell by 1.22% (-275.80 points) to 22,269.25. Glenmark dropped by 2.43%, closing at ₹1,...
Biocon launches Liraglutide for diabetes and obesity in the UK
Biocon Limited, a global biopharmaceutical leader, has announced the launch of its GLP-1 peptide, Liraglutide, in the United Kingdom (U.K.) for diabetes and chronic weight management. The drug will be...
Biocon shares surge 2.2% after its subsidiary launches YESINTEK™ in the US
Biocon Ltd. shares rose over 2% following the U.S. launch of YESINTEK™ (ustekinumab-kfce) by its subsidiary, Biocon Biologics Ltd. (BBL). As one of the first biosimilars to Stelara® (ustekinumab), YES...
Top stocks to watch today on February 25: Biocon, NTPC, Adani Green, Texmaco Rail and more
The Indian stock market is expected to open on a cautious note on Tuesday, influenced by multiple global and domestic factors. Market sentiment remains uncertain due to former U.S. President Donald Tr...
Biocon Biologics launches YESINTEK™ in the United States
Biocon Biologics Ltd. (BBL), a leading global biosimilars company and a subsidiary of Biocon Ltd., has announced the availability of YESINTEK™ (ustekinumab-kfce) in the United States. As one of the fi...